AU2022290019A1 - Nitroxoline for use in the treatment of cutaneous neurofibroma - Google Patents

Nitroxoline for use in the treatment of cutaneous neurofibroma Download PDF

Info

Publication number
AU2022290019A1
AU2022290019A1 AU2022290019A AU2022290019A AU2022290019A1 AU 2022290019 A1 AU2022290019 A1 AU 2022290019A1 AU 2022290019 A AU2022290019 A AU 2022290019A AU 2022290019 A AU2022290019 A AU 2022290019A AU 2022290019 A1 AU2022290019 A1 AU 2022290019A1
Authority
AU
Australia
Prior art keywords
composition
nitroxoline
use according
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022290019A
Other languages
English (en)
Inventor
David Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Healx Ltd
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of AU2022290019A1 publication Critical patent/AU2022290019A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022290019A 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma Pending AU2022290019A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108224.3A GB202108224D0 (en) 2021-06-09 2021-06-09 Treatment
GB2108224.3 2021-06-09
PCT/GB2022/051442 WO2022258972A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma

Publications (1)

Publication Number Publication Date
AU2022290019A1 true AU2022290019A1 (en) 2023-12-14

Family

ID=76838879

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022290019A Pending AU2022290019A1 (en) 2021-06-09 2022-06-09 Nitroxoline for use in the treatment of cutaneous neurofibroma

Country Status (12)

Country Link
US (1) US20240261276A1 (https=)
EP (1) EP4351576A1 (https=)
JP (1) JP2024520690A (https=)
KR (1) KR20240024175A (https=)
CN (1) CN117769419A (https=)
AU (1) AU2022290019A1 (https=)
BR (1) BR112023025789A2 (https=)
CA (1) CA3221964A1 (https=)
GB (1) GB202108224D0 (https=)
IL (1) IL309177A (https=)
MX (1) MX2023014530A (https=)
WO (1) WO2022258972A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202116743D0 (en) * 2021-11-19 2022-01-05 Healx Ltd Treatment
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3039822C (en) * 2016-10-14 2026-02-17 Wake Forest University Health Sciences Compositions, cell constructs, and methods of making and using the same

Also Published As

Publication number Publication date
GB202108224D0 (en) 2021-07-21
CN117769419A (zh) 2024-03-26
CA3221964A1 (en) 2022-12-15
EP4351576A1 (en) 2024-04-17
MX2023014530A (es) 2024-04-10
WO2022258972A1 (en) 2022-12-15
JP2024520690A (ja) 2024-05-24
BR112023025789A2 (pt) 2024-02-27
KR20240024175A (ko) 2024-02-23
US20240261276A1 (en) 2024-08-08
IL309177A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
Huang et al. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment
KR100891568B1 (ko) 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법
JP5424923B2 (ja) 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
CN103533930A (zh) 用于治疗神经性疼痛的大麻素类化合物
JP2006512281A (ja) 乾癬及び他の皮膚疾患治療におけるシクロパミンの使用
US20240261276A1 (en) Nitroxoline for use in the treatment of cutaneous neurofibroma
US20250000852A1 (en) Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma
CN121197400A (zh) 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
Shrikhande The consideration of endometriosis in women with persistent gastrointestinal symptoms and a novel neuromusculoskeletal treatment approach
Li et al. Sciatic nerve block combined with flurbiprofen inhibits spinal cord inflammation and improves postoperative pain in rats with plantar incision
US20160000804A1 (en) Inhibitors of na(v) 1.9 channel activity and uses thereof for treating pain
WO2019197632A1 (en) Treatment of fragile x syndrome
US12599617B2 (en) Methods of treating head and neck cancers with hemp extract
Ren et al. Sappanone A Promotes Motor Function Recovery in Spinal Cord Injury Mice by Inhibiting Microglial M1 Polarization via Activation of the Keap1/Nrf2 Pathway
Li et al. [Retracted] Application of General Anesthesia Combined with Saphenous Nerve‐Tibial Nerve Block in Total Knee Arthroplasty
Nabiya et al. Identification of Fungal Bioactive Compounds Targeting MMP-9 for Endometriosis-An In silico Approach
El-Dwairi et al. Sildenafil effect on testosterone-induced prostate hypertrophy and relaxation of urinary bladder neck muscles
CA3149702A1 (en) Treatment of fragile x syndrome
WO2010120203A1 (ru) Применение органических красителей в качестве обезболивающих средств
CN102258512A (zh) Ag490在预防和治疗腹主动脉瘤的用途
HK1174565B (en) Method of treating scars and ss-catenin-mediated disorders using nefopam compounds
HK1174565A1 (zh) 使用奈福泮化合物治疗瘢痕和β-联蛋白介导的疾病的方法